Forest Labs Will Acquire Furiex | Chemical & Engineering News
Volume 92 Issue 18 | p. 15 | Concentrates
Issue Date: May 5, 2014

Forest Labs Will Acquire Furiex

Department: Business
Keywords: pharmaceuticals, acquisition, specialty pharma, generics, gastroenterology

Forest Laboratories will pay up to $1.5 billion to purchase Furiex Pharmaceuticals of Morrisville, N.C. Furiex expects to apply soon for FDA approval for its lead product, eluxadoline, a treatment for irritable bowel syndrome. Forest has agreed to sell Furiex’s royalties on two other drugs to Royalty Pharma for $415 million, provided the deal goes through. Forest expanded its gastroenterology business earlier this year by acquiring the specialty pharma firm Aptalis for $2.9 billion. Meanwhile, the generic drug maker Actavis is in the process of acquiring Forest for $25 billion.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment